Regado Slashes Price To Complete Offering Amidst A Mixed IPO Field
This article was originally published in The Pink Sheet Daily
The New Jersey-based anticoagulant developer cut its share price by roughly two-thirds, but offered more shares to compensate. It’s a big haircut, during a period when some other offerings are exceeding expectations.
You may also be interested in...
Encouraging results from some early 2013 offerings have led to four new filings in April. If the pattern holds, this year could be a better year for new listings than 2012.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.